Found: 71
Select item for more details and to access through your institution.
Preclinical comparison of [<sup>177</sup>Lu]Lu-rhPSMA-10.1 and [<sup>177</sup>Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies.
- Published in:
- EJNMMI Radiopharmacy & Chemistry, 2024, v. 9, n. 1, p. 1, doi. 10.1186/s41181-024-00246-2
- By:
- Publication type:
- Article
Galectin-3 and cancer immunotherapy: a glycobiological rationale to overcome tumor immune escape.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2024, v. 43, n. 1, p. 1, doi. 10.1186/s13046-024-02968-2
- By:
- Publication type:
- Article
Comparative Analysis of Morphological and Functional Effects of 225 Ac- and 177 Lu-PSMA Radioligand Therapies (RLTs) on Salivary Glands.
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 23, p. 16845, doi. 10.3390/ijms242316845
- By:
- Publication type:
- Article
Improved Quality of Life in Metastatic Castration-Resistant Prostate Cancer Patients Receiving Consecutive Cycles of <sup>177</sup>Lu-PSMA I&T.
- Published in:
- Journal of Nuclear Medicine, 2023, v. 64, n. 11, p. 1765, doi. 10.2967/jnumed.123.265878
- By:
- Publication type:
- Article
Safety and Efficacy of [<sup>177</sup>Lu]-PSMA-I&T Radioligand Therapy in Octogenarians with Metastatic Castration-Resistant Prostate Cancer: Report on 80 Patients over the Age of 80 Years.
- Published in:
- Journal of Nuclear Medicine, 2023, v. 64, n. 8, p. 1244, doi. 10.2967/jnumed.122.265259
- By:
- Publication type:
- Article
The Impact of PSMA PET--Based Eligibility Criteria Used in the Prospective Phase II TheraP Trial in Metastatic Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen--Targeted Radioligand Therapy.
- Published in:
- Journal of Nuclear Medicine, 2023, v. 64, n. 8, p. 1252, doi. 10.2967/jnumed.122.265346
- By:
- Publication type:
- Article
Prognostic Role of <sup>68</sup>Ga-PSMA11 PET–Based Response in Patients with Prostate Cancer Undergoing Taxane-Based Chemotherapy.
- Published in:
- Journal of Nuclear Medicine, 2023, v. 64, n. 6, p. 896, doi. 10.2967/jnumed.122.264962
- By:
- Publication type:
- Article
<sup>177</sup>Lu-PSMA-I&T for Treatment of Metastatic Castration-Resistant Prostate Cancer: Prognostic Value of Scintigraphic and Clinical Biomarkers.
- Published in:
- Journal of Nuclear Medicine, 2023, v. 64, n. 3, p. 402, doi. 10.2967/jnumed.122.264402
- By:
- Publication type:
- Article
Promise and challenges of clinical non-invasive T-cell tracking in the era of cancer immunotherapy.
- Published in:
- EJNMMI Research, 2022, v. 12, n. 1, p. 1, doi. 10.1186/s13550-022-00877-z
- By:
- Publication type:
- Article
<sup>177</sup>Lu-PSMA-I&T for treatment of metastatic castration resistant prostate cancer: prognostic value of scintigraphic and clinical biomarkers.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 10, p. 1, doi. 10.2967/jnumed.122.264402
- By:
- Publication type:
- Article
Synthesis and Preclinical Evaluation of <sup>177</sup>Lu-labeled Radiohybrid PSMA Ligands (rhPSMAs) for Endoradiotherapy of Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 10, p. 1, doi. 10.2967/jnumed.121.263371
- By:
- Publication type:
- Article
<sup>177</sup>Lu-PSMA-I&T for treatment of metastatic castration resistant prostate cancer: prognostic value of scintigraphic and clinical biomarkers.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 9, p. 1, doi. 10.2967/jnumed.122.264402
- By:
- Publication type:
- Article
Synthesis and Preclinical Evaluation of <sup>177</sup>Lu-labeled Radiohybrid PSMA Ligands (rhPSMAs) for Endoradiotherapy of Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 9, p. 1, doi. 10.2967/jnumed.121.263371
- By:
- Publication type:
- Article
Synthesis and Preclinical Evaluation of <sup>177</sup>Lu-labeled Radiohybrid PSMA Ligands (rhPSMAs) for Endoradiotherapy of Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 7, p. 1, doi. 10.2967/jnumed.121.263371
- By:
- Publication type:
- Article
Synthesis and Preclinical Evaluation of <sup>177</sup>Lu-labeled Radiohybrid PSMA Ligands (rhPSMAs) for Endoradiotherapy of Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 6, p. 1, doi. 10.2967/jnumed.121.263371
- By:
- Publication type:
- Article
Synthesis and Preclinical Evaluation of <sup>177</sup>Lu-labeled Radiohybrid PSMA Ligands (rhPSMAs) for Endoradiotherapy of Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 5, p. 1, doi. 10.2967/jnumed.121.263371
- By:
- Publication type:
- Article
Synthesis and Preclinical Evaluation of <sup>177</sup>Lu-labeled Radiohybrid PSMA Ligands (rhPSMAs) for Endoradiotherapy of Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 3, p. 1, doi. 10.2967/jnumed.121.263371
- By:
- Publication type:
- Article
Preclinical biodistribution and dosimetry and human biodistribution comparing <sup>18</sup>F-rhPSMA-7 and single isomer <sup>18</sup>F-rhPSMA-7.3.
- Published in:
- EJNMMI Research, 2022, v. 12, n. 1, p. 1, doi. 10.1186/s13550-021-00872-w
- By:
- Publication type:
- Article
Synthesis and Preclinical Evaluation of <sup>177</sup>Lu-labeled Radiohybrid PSMA Ligands (rhPSMAs) for Endoradiotherapy of Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 2, p. 1, doi. 10.2967/jnumed.121.263371
- By:
- Publication type:
- Article
Promise and challenges of clinical non-invasive T-cell tracking in the era of cancer immunotherapy.
- Published in:
- EJNMMI Research, 2022, v. 12, n. 1, p. 1, doi. 10.1186/s13550-022-00877-z
- By:
- Publication type:
- Article
Pre-therapeutic comparative dosimetry of <sup>177</sup>Lu-rhPSMA-7.3 and <sup>177</sup>Lu-PSMA-I&T in patients with metastatic castration resistant prostate cancer (mCRPC).
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.121.262671
- By:
- Publication type:
- Article
Detection efficacy of <sup>18</sup>F‐rhPSMA‐7.3 PET/CT and impact on patient management in patients with biochemical recurrence of prostate cancer after radical prostatectomy and prior to potential salvage treatment.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.120.260091
- By:
- Publication type:
- Article
Pre-therapeutic comparative dosimetry of <sup>177</sup>Lu-rhPSMA-7.3 and <sup>177</sup>Lu-PSMA-I&T in patients with metastatic castration resistant prostate cancer (mCRPC).
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.121.262671
- By:
- Publication type:
- Article
Detection efficacy of 18F‐rhPSMA‐7.3 PET/CT and impact on patient management in patients with biochemical recurrence of prostate cancer after radical prostatectomy and prior to potential salvage treatment.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.120.260091
- By:
- Publication type:
- Article
Pre-therapeutic comparative dosimetry of <sup>177</sup>Lu-rhPSMA-7.3 and <sup>177</sup>Lu-PSMA-I&T in patients with metastatic castration resistant prostate cancer (mCRPC).
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.121.262671
- By:
- Publication type:
- Article
Detection efficacy of <sup>18</sup>F‐rhPSMA‐7.3 PET/CT and impact on patient management in patients with biochemical recurrence of prostate cancer after radical prostatectomy and prior to potential salvage treatment.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.120.260091
- By:
- Publication type:
- Article
A Semi Rigid Novel Hydroxamate AMPED-Based Ligand for 89 Zr PET Imaging.
- Published in:
- Molecules, 2021, v. 26, n. 19, p. 5819, doi. 10.3390/molecules26195819
- By:
- Publication type:
- Article
Detection efficacy of <sup>18</sup>F-rhPSMA-7.3 PET/CT and impact on patient management in patients with biochemical recurrence of prostate cancer after radical prostatectomy and prior to potential salvage treatment.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1, doi. 10.2967/jnumed.120.260091
- By:
- Publication type:
- Article
Comparative Preclinical Biodistribution, Dosimetry, and Endoradiotherapy in Metastatic Castration-Resistant Prostate Cancer Using <sup>19</sup>F/<sup>177</sup>Lu-rhPSMA-7.3 and <sup>177</sup>Lu-PSMA I&T.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1106, doi. 10.2967/jnumed.120.254516
- By:
- Publication type:
- Article
Is Hypoxia a Factor Influencing PSMA-Directed Radioligand Therapy?—An In Silico Study on the Role of Chronic Hypoxia in Prostate Cancer.
- Published in:
- Cancers, 2021, v. 13, n. 14, p. 3429, doi. 10.3390/cancers13143429
- By:
- Publication type:
- Article
Detection efficacy of <sup>18</sup>F-rhPSMA-7.3 PET/CT and impact on patient management in patients with biochemical recurrence of prostate cancer after radical prostatectomy and prior to potential salvage treatment.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 7, p. 1, doi. 10.2967/jnumed.120.260091
- By:
- Publication type:
- Article
Detection efficacy of <sup>18</sup>F-rhPSMA-7.3 PET/CT and impact on patient management in patients with biochemical recurrence of prostate cancer after radical prostatectomy and prior to potential salvage treatment.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 6, p. 1, doi. 10.2967/jnumed.120.260091
- By:
- Publication type:
- Article
Detection efficacy of <sup>18</sup>F-rhPSMA-7.3 PET/CT and impact on patient management in patients with biochemical recurrence of prostate cancer after radical prostatectomy and prior to potential salvage treatment.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 5, p. 1, doi. 10.2967/jnumed.120.260091
- By:
- Publication type:
- Article
Effective rational humanization of a PASylated anti-galectin-3 Fab for the sensitive PET imaging of thyroid cancer in vivo.
- Published in:
- Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-86641-0
- By:
- Publication type:
- Article
Imaging atherosclerotic plaques by targeting Galectin-3 and activated macrophages using (<sup>89</sup>Zr)-DFO-Galectin3-F(ab')<sub>2</sub> mAb.
- Published in:
- Theranostics, 2021, v. 11, n. 4, p. 1864, doi. 10.7150/thno.50247
- By:
- Publication type:
- Article
Positive predictive value and correct detection rate of <sup>18</sup>F-rhPSMA-7 PET in biochemically recurrent prostate cancer validated by composite reference standard.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 12, p. 1, doi. 10.2967/jnumed.120.255661
- By:
- Publication type:
- Article
Early prostate-specific antigen changes and clinical outcome following <sup>177</sup>Lu-PSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 12, p. 1, doi. 10.2967/jnumed.119.240242
- By:
- Publication type:
- Article
Early prostate-specific antigen changes and clinical outcome following <sup>177</sup>Lu-PSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 11, p. 1, doi. 10.2967/jnumed.119.240242
- By:
- Publication type:
- Article
Early prostate-specific antigen changes and clinical outcome following <sup>177</sup>Lu-PSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 10, p. 0, doi. 10.2967/jnumed.119.240242
- By:
- Publication type:
- Article
Early prostate-specific antigen changes and clinical outcome following <sup>177</sup>Lu-PSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 9, p. 1, doi. 10.2967/jnumed.119.240242
- By:
- Publication type:
- Article
Development of a Chimeric Antigen-Binding Fragment Directed Against Human Galectin-3 and Validation as an Immuno-Positron Emission Tomography Tracer for the Sensitive In Vivo Imaging of Thyroid Cancer.
- Published in:
- Thyroid, 2020, v. 30, n. 9, p. 1314, doi. 10.1089/thy.2019.0670
- By:
- Publication type:
- Article
Early prostate-specific antigen changes and clinical outcome following 177Lu-PSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 8, p. 0, doi. 10.2967/jnumed.119.240242
- By:
- Publication type:
- Article
Early prostate-specific antigen changes and clinical outcome following <sup>177</sup>Lu-PSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 7, p. 1, doi. 10.2967/jnumed.119.240242
- By:
- Publication type:
- Article
Early prostate-specific antigen changes and clinical outcome following <sup>177</sup>Lu-PSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 6, p. 1, doi. 10.2967/jnumed.119.240242
- By:
- Publication type:
- Article
Early prostate-specific antigen changes and clinical outcome following 177Lu-PSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 5, p. 1, doi. 10.2967/jnumed.119.240242
- By:
- Publication type:
- Article
Early prostate-specific antigen changes and clinical outcome following <sup>177</sup>Lu-PSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 4, p. 1, doi. 10.2967/jnumed.119.240242
- By:
- Publication type:
- Article
Early prostate-specific antigen changes and clinical outcome following <sup>177</sup>Lu-PSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 3, p. 1, doi. 10.2967/jnumed.119.240242
- By:
- Publication type:
- Article
Room Temperature Al<sup>18</sup>F Labeling of 2‐Aminomethylpiperidine‐Based Chelators for PET Imaging.
- Published in:
- ChemMedChem, 2020, v. 15, n. 3, p. 284, doi. 10.1002/cmdc.201900652
- By:
- Publication type:
- Article
Exceptional 4-year response to <sup>177</sup>Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2019, v. 46, n. 10, p. 2212, doi. 10.1007/s00259-019-04410-8
- By:
- Publication type:
- Article
Galectin-3 Targeting in Thyroid Orthotopic Tumors Opens New Ways to Characterize Thyroid Cancer.
- Published in:
- Journal of Nuclear Medicine, 2019, v. 60, n. 6, p. 770, doi. 10.2967/jnumed.118.219105
- By:
- Publication type:
- Article